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SUMMARY
Objective: An estimated 6–10 million people in India live with active epilepsy, and less
than half are treated. We analyze the health and economic benefits of three scenarios
of publicly financed national epilepsy programs that provide: (1) first-line antiepilepsy
drugs (AEDs), (2) first- and second-line AEDs, and (3) first- and second-line AEDs and
surgery.
Methods: We model the prevalence and distribution of epilepsy in India using India-
Sim, an agent-based, simulation model of the Indian population. Agents in the model
are disease-free or in one of three disease states: untreated with seizures, treated with
seizures, and treated without seizures. Outcome measures include the proportion of
the population that has epilepsy and is untreated, disability-adjusted life years (DALYs)
averted, and cost per DALY averted. Economic benefit measures estimated include
out-of-pocket (OOP) expenditure averted andmoney-metric value of insurance.
Results: All three scenarios represent a cost-effective use of resources and would avert
800,000–1 million DALYs per year in India relative to the current scenario. However,
especially in poor regions and populations, scenario 1 (which publicly finances only
first-line therapy) does not decrease the OOP expenditure or provide financial risk
protection if we include care-seeking costs. The OOP expenditure averted increases
from scenarios 1 through 3, and the money-metric value of insurance follows a similar
trend between scenarios and typically decreases with wealth. In the first 10 years of
scenarios 2 and 3, households avert on average over US$80 million per year in medical
expenditure.
Significance: Expanding and publicly financing epilepsy treatment in India averts sub-
stantial disease burden. A universal public finance policy that covers only first-line
AEDs may not provide significant financial risk protection. Covering costs for both
first- and second-line therapy and other medical costs alleviates the financial burden
from epilepsy and is cost-effective across wealth quintiles and in all Indian states.
KEY WORDS: Epilepsy, India, Cost-effectiveness, Agent-based model, Universal
public finance.
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1
FULL-LENGTHORIGINALRESEARCH
Roughly 80% of the 50 million people globally who have
epilepsy live in low- and middle-income countries
(LMICs).1 Most cases of epilepsy can be effectively treated
using first-line drugs,2 which are cost-effective,3–5 but poor
knowledge and stigma, low prioritization within the health
system, high out of pocket costs, and lack of human
resources, diagnostic facilities, and drug supply have led to
a large number of untreated epilepsy cases,1,6–14 and conse-
quently a high disease burden in these countries. In 2010,
epilepsy caused approximately 17.4 million disability-
adjusted life years (DALYs) globally. Globally, epilepsy
ranks 20th as a cause of years lived with disability.15
An estimated 6–10 million individuals live with active
epilepsy in India,11,16,17 but less than half receive appropri-
ate and sufficient epilepsy treatment.6 To overcome the
treatment gap and improve quality of care for people with
epilepsy, India’s Ministry of Health and FamilyWelfare has
proposed the creation of a national epilepsy program to
increase public awareness about epilepsy, train healthcare
workers to better identify the disease, and provide first- and
second-line antiepileptic drugs (AEDs).11 Experts have also
noted the need for an epilepsy surgery program in
India.14,18–20 In 1998, the per patient cost of epilepsy treat-
ment was as high as 88.2% of the country’s per capita gross
national product (GNP), and epilepsy-related costs, which
includes medical costs, travel, and lost work time, exceeded
$2.6 billion (2013 USD).21
We evaluate the health and economic benefits of a
national program that finances and expands coverage of epi-
lepsy treatment in India. Using IndiaSim,22–24 an agent-
based simulation model (ABM) of India’s population and
health system, we examine the incremental impact of imple-
menting three universal public finance (UPF) policy scenar-
ios. In scenario 1, the program provides first-line AEDs. In
scenario 2, the program provides both first- and second-line
Key Points
• The high burden of epilepsy in India impacts house-
holds financially in addition to disease-related
burdens
• Provision of first-line antiepileptic drugs (AEDs) can
significantly reduce the disease burden and is cost-
effective
• Cost-effectiveness analyses of mental health disorders
are a useful tool for policy decisions, but they do not
capture the financial burden on households
• Public finance of first-line AEDs does not necessarily
protect households from financial shock if we consider
care-seeking costs
• A program that publically finances second-line AEDs
provides better financial risk protection for the Indian
population
AEDs. In scenario 3, first-line AEDs, second-line AEDs,
and epilepsy surgery are publicly financed. In each scenario
the program increases coverage of the specified interven-
tions to 80% through public and private provision, and it
covers related medical expenditures—diagnostics, outpa-
tient consultation, and inpatient costs. For each scenario we
conduct an extended cost-effectiveness analysis (ECEA)25
by estimating the policies’ impacts on five measures:
DALYs averted, incremental government expenditure,
incremental dollars per DALY averted or the incremental
cost-effectiveness ratio (ICER), out-of-pocket (OOP)
expenditure averted, and the money-metric value of insur-
ance.
Methods
Model
IndiaSim is representative of the Indian population and
health system at the district level. Details about IndiaSim
are in Appendix S1 and in earlier publications.22,23 We use
it to model a baseline scenario with a treatment gap of
64.3%26 and intervention scenarios with 80% effective cov-
erage for patients with epilepsy.
The disease model is presented in Figure 1. Healthy indi-
viduals acquire epilepsy at a daily rate Λi,j, for age group i
of gender j, and move into the “epilepsy without treatment”
state. They clear the disease without treatment at the remis-
sion rate rN,i,j. Those in epilepsy states die at the rate of
excess mortality (Table S1).
The model includes three treatment options for patients
with epilepsy: first-line AEDs, lamotrigine, and surgery.
Lamotrigine is an example of a new-generation AED as the
second-line treatment. First-line drugs are prescribed
according to the frequency distribution in Table 1.2 Those
who seek and receive treatment (at the rate c1) move into the
“epilepsy with first-line therapy” category. A proportion of
patients, a, adhere to the treatment. Patients treated with
first-line therapy who continue to experience epileptic sei-
zures after 2 months are switched to second-line treatment
if they are covered (c2) and move into “epilepsy with sec-
ond-line therapy” state. A third of these patients are eligible
for surgery (randomly selected in the model) and the rest are
treated with lamotrigine. Because epilepsy surgery is expen-
sive and available data indicate that <500 surgeries are per-
formed each year in India,14,20 we assume that at baseline,
only the top 1% of the population income distribution is able
to pay for surgery. Patients who are eligible for surgery but
cannot afford it are treated with lamotrigine. Patients who
adhere to treatment and stop experiencing seizures naturally
or due to treatment at rates rt1 (first-line therapy) and rt2
(second-line therapy) continue being treated with AEDs for
5 years, at which point they move into the “seizure-free
with first/second line therapy” state. They continue to be
defined to have active epilepsy for a mean period 1/s, set to
5 years in our model.
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We consider the costs for implementing the program, cal-
culated with the World Health Organization (WHO) Mental
Health Gap Action Programme (mhGAP) tool, in addition
to patients’ medical and care-seeking costs. See Tables 1
and S1 for model parameters and costs.
Analysis
We conduct analysis of IndiaSim output using R (version
3.1.2) and report health and economic outcomes at state and
national levels for the first 10 years of intervention. Health
burden is measured in DALYs. Economic impact is mea-
sured using ICERs and epilepsy-specific OOP expenditure
averted. Financial risk protection is measured by the
money-metric value of insurance—the price individuals are
willing to pay to avoid the risk of financial shock.25,27 We
report the mean present value for the 10 years, discounted
at 3% annually. Costs and expenditures are in 2013 US dol-
lars. We conduct a Latin Hypercube Sampling (LHS) sensi-
tivity analysis and construct 95% uncertainty ranges (URs).
Further details on these calculations are in Appendix S1.
Results
The outcomes for the UPF policies are in Table 2 and in
Figures 2–4.
Health benefits
The model predicts roughly 7 million total active epilepsy
cases—individuals with epileptic seizures in the last 5 years
—in India at baseline. By the sixth year, the UPF policies
relieve the burden of active epilepsy cases by approximately
1.5–2 million across India and significantly increase the
number of treated patients among those with active epi-
lepsy.
Figure 2 presents prevalence rates for the key health
states of the model (treated and seizure-free, treated with
seizures, and untreated with seizures) over 10 years for each
scenario. Prevalence of treated and seizure-free patients is
highest in the first 5 years in UPF scenarios 1 through 3
(close to five times the baseline prevalence). Prevalence
drops significantly when patients who stopped experiencing
seizures in year 1 are no longer medically considered to
have active epilepsy in year 6 (approximately 2.1–2.3 times
the baseline prevalence in scenarios 1 through 3).
The burden of untreated individuals with epilepsy decli-
nes by roughly 43% (UR 40–45%), 50% (UR 48–52%), and
52% (UR 50–54%) in scenarios 1 through 3, relative to
baseline. It increases with nonadherence to treatment. In
year 10 of scenario 3, there is approximately 44% (UR 42–
46%) fewer untreated individuals with epilepsy than at
baseline.
Total DALYs averted in UPF scenarios are presented in
Table 2. Over 10 years, treatment in the baseline scenario
averts 580 (UR 545–595) DALYs per 100,000 individuals
compared to no treatment. Over the same period, in scenario
1, 835 (UR 805–870) DALYs per 100,000 persons are
averted incremental to the baseline. In scenario 2 an addi-
tional 65 (UR 56–76) DALYs per 100,000 are averted, and
Figure 1.
Epilepsy model Λi,j is the incidence rate for age group i of sex j; c1 and c2 are the effective coverage of first- (first-line AEDs) and second-
line (lamotrigine or surgery along with first-line AED) therapy; 1-a is the treatment dropout rate due to adherence; rN,i,j is the natural
clearance rate for age group i of gender j, and rt1 and rt2 are the clearance rates with therapy; and s is the rate of stopping treatment
when not having seizures. Those in the seizure-free with therapy state are still medically considered to have active epilepsy. Individuals
are born into the healthy and seizure-free category. They die from exogenous causes (in any state) or epilepsy-related causes (in states
with active epilepsy) and are removed from the model.
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in scenario 3 an additional 44 (UR 35–53) DALYs incre-
mental to scenario 2. That amounts to approximately
800,000 DALYs averted each year in the baseline, and 1.8–
2.3 million DALYs averted in scenarios 1 through 3 (Fig. 3
row 2 column 2).
At baseline, treatment averts more DALYs in rich popu-
lations (e.g., 125 UR 110–135/20,000 in the richest quintile
over the 10 years) than in poor ones (e.g., 100 UR 90–110/
20,000 in the poorest quintile) compared to the no treatment
scenario. The UPF policies flatten the distribution of
DALYs averted by the treatment interventions across
wealth quintiles (Table 2). In scenario 1, treatment averts
160 (UR 150–170) DALYs per 20,000 (incremental to the
baseline) in the richest 20% and 175 (UR 165–185) DALYs
in the poorest 20%.
Goa and Maharashtra have the highest rates of averted
DALYs (e.g., 1,350 UR 1,010–1,690 and 1,010 UR 950–
1,065 DALYs averted per 100,000 in scenario 3 in Goa and
Maharashtra), although the differences between states are
not large (Fig. 4 row 1 and Figs. S1–S4 in the Appendix
S1). In absolute numbers the differences are far greater. The
most DALYs are averted in Uttar Pradesh (298,950 UR
289,440–308,470 DALYs averted in the mean year in sce-
nario 3), and combined with Bihar, Madhya Pradesh, and
Rajasthan it accounts for >50% of the DALYs averted in
India in each UPF scenario. Those states also have the great-
est burden in the baseline.
Government expenditures
The sequential, incremental present day government
expenditure (including diagnostics, AEDs, surgeries, and
medical consultation) in the first 10 years of the scenarios
(Table 2) is: $145,090 (UR $141,860–$148,230)/100,000
persons in scenario 1; $107,590 (UR $97,360–$117,430)/
100,000 in scenario 2; and $77,720 (UR $68,770–$86,650) in
scenario 3. The government spends the most money in the
first 5 years of the UPF scenarios (Fig. 3 row 2 column 1).
After 5 years, many new patients will no longer have active
epilepsy and will stop treatment, so government costs will
drop. The costs are especially high at the initial stages of sce-
nario 3 when surgery is available to many new patients. Only
50–500 surgeries are performed each year in the status quo
and in UPF scenarios 1 and 2. Approximately 400,000 surg-
eries need to be performed in the initial stages of scenario 3 to
Table 1. Treatment input parameters
Variable Value Sensitivity range Source
Treatment parameters
Treatment gap 64.3% 45–84% Mbuba et al. 200826 and distributed
according to NSS 60th round schedule 2531
Adherence 70% 49–91% Chisholm 20053
1st-line AED distribution Range shown
in costs
Phenobarbital (30 mg) 50% Authors’ assumption
Carbamazepine (200 mg) 30%
Phenytoin (100 mg) 10%
Valproate (200 mg) 10%
Second-line treatment distribution
Second-line AED (lamotrigine) 67% Authors’ assumption
Surgery 33%
% respond to treatment
First-line AED 70% 49–91% Annegers et al. 197935
Second-line AED 42% 29–55% Schiller & Najjar 200836
Surgery 64% 44–84% Engel et al. 200337
Cost parameters
Drugs: retail price (annual) Median price of brands fromCIMS38
First-line AED $34.19 $23–$45 Weighted by first-line distribution
Second-line AED $211.37 $147–$275
Drugs: government purchase price (annual)
First-line AED $23.33 $16.33–$30.33 Calculated from the International
Drug Price Indicator
Guide39 and usingWHOCIF multipliers40
Second-line AED $125.42 $87.79–$163.05
Average annual costs
Nonsurgical medical costsa $34.91 $24–$45 Thomas et al. 200121
Travel cost $25.09 $17–$33
Surgery costs (one-time)
Surgery-related medical costs $1,646.13 $1,152–$2,140 Calculated from Rao & Radhakrishnan 2000,18
excluding AEDs and non-surgical medical costs
Travel cost $50.17 $35–$66 Authors’ assumption, based on Thomas et al. 200121
aIncludes outpatient consultation, diagnostic investigation, and hospitalization; costs have been inflated to 2013 prices using GDP deflators.
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cover 80% of eligible existing epilepsy cases (who do not
respond to first-line therapy), and following the initial stage,
40,000–50,000 surgeries need to be performed each year. See
Figure 4 row 2 and Figures S5–S7 for state-wise values.
Private, out-of-pocket expenditures
There is no significant OOP expenditure averted in UPF
scenario 1. Mean OOP expenditure increases by $17,230
(UR $12,740–$23,010)/100,000 in the first 10 years
(Table 2). The policies in the scenario save $19,740 (UR
$18,780–$20,690) out of pocket per 100,000 on first-line
therapy and $20,150 (UR $19,170–$21,130) on other medi-
cal costs, but those savings are countered by new patients’
care-seeking costs (approximately $27,000/100,000) and
increase in second-line drug purchases (approximately
$30,000/100,000 not covered in scenario 1) if patients do
not respond to first-line therapy and choose to continue
treatment. Similarly to government expenditure, OOP
expenditure drops when new patients experience remission
and stop treatment. In year 7, the scenario’s policies avert
$750 (UR $190–$1,310) OOP expenditure per 100,000 rela-
tive to the baseline, and in year 10 they avert $1,510 (UR
$980–$2,040).
Policies in scenarios 2 and 3 avert OOP expenditure as
a result of the increased public financing. In the first
10 years of scenario 2, OOP expenditure averted is
$75,760 (UR $68,000–$83,160)/100,000 incremental to
scenario 1, and the OOP expenditure averted in scenario
3 is similar. The range of the rates of OOP expenditure
averted per 100,000 across states is relatively small—
from approximately $45,000 to $72,000 averted in the
first 10 years of scenario 2 and slightly more in scenario
3 (Fig. 3 row 3 and Figs. S8–S10 in Appendix S1). On
average over $80 million OOP expenditure is averted in
India per year in both scenarios 2 and 3, although the
value is approximately $40–$60 million in the first few
years. Only the top 1% of the population has more OOP
expenditure averted in scenario 3 than in scenario 2
(Table 2) because others do not pay for surgeries in the
baseline.
Cost-effectiveness
The sequential ICERs relative to no treatment are pre-
sented in Figure 3: $190 (UR $175–$205) in the baseline,
$194 (UR $185–$204) per DALY averted in scenario 1,
$483 (UR $355–$611) in scenario 2, and $1,790 (UR
$1,448–$2,131) in scenario 3. The dollars per DALY
averted with respect to no treatment—that is, the average
cost-effective ratios—are $158 (UR $149–$167), $173 (UR
$163–$183) and $220 (UR $206–$234) in scenarios 1, 2,
Figure 2.
Prevalence of active epilepsy over time. Results are over100 simulations. The plot includes only individuals with active epilepsy-seizure in
the last 5 years. The treated and seizure-free group includes those that have not had recent seizures, but have had seizures in the last
5 years. Baseline effective coverage for first-line and second-line therapy is 36% and treatment is paid out of pocket. All policy scenarios
cover the annual medical costs (consultation, diagnostics, and inpatient). In scenario 1, effective coverage for first-line therapy is 80%, and
effective coverage for second-line therapy is 36%. Second-line treatment and surgery are paid out of pocket. In scenario 2, effective cover-
age for first-line and second-line therapy is 80%, and only surgery is paid out of pocket. In scenario 3, effective coverage for first-line and
second-line therapy is 80%, and no treatment is paid out of pocket. Only the top 1% of the population chooses to undergo surgery when
it is covered out of pocket.
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and 3, respectively. All three policy scenario are “very cost-
effective” under WHO guidelines.28
Financial risk protection
The sequential, incremental money-metric value of
insurance sum of the first 10 years of the policies is
$15,210 ($16,470 to $13,940)/100,000 in scenario 1,
$65,360 ($60,180–$70,530)/100,000 in scenario 2, and
$2,600 ($2,050–$3,150) in scenario 3 (Table 2). The UPF
in scenario 1 does not offer financial risk protection. This
affects the poor the most because they increase their effec-
tive coverage and their travel frequency the most
(Table 2). Poor states such as Bihar, which has a money-
metric value of insurance of $53,010 (UR $62,360 to
$43,660)/100,000 summed over the 10 years, also suffer
financially.
In scenarios 2 and 3, the trend of financial risk protection
across the wealth distribution flips from the distribution in
scenario 1. In scenario 2 the poor have the highest financial
risk protection ($30,770 UR $26,200–$35,340/20,000 in
quintile I in the 20 years), and the rich have the least protec-
tion ($1,270 UR $730–$1,810 in quintile V). In this scenario
the money-metric value of insurance is extremely high in
Bihar at $223,890 (UR $184,680–$263,100)/100,000, and it
is also above $100,000 inManipur and Uttar Pradesh (Fig. 3
row 4 and Fig. S12; for scenarios 1 and 3 also see figures
S11 and S13, respectively). The rich and rich states have
higher protection in scenario 3 than in scenario 2 (e.g.,
financial risk protection in Delhi is approximately $13,000
higher, whereas it is $1,000 lower in Bihar).
Discussion
In this article, we compute the health and financial bene-
fits of expanding coverage and publicly financing epilepsy
treatment in India. Although past analyses find epilepsy
treatment is cost-effective in LMICs,3–5,29,30 severe
undertreatment of epilepsy persists. We evaluate a hypo-
thetical national epilepsy program and demonstrate the
incremental benefits to various Indian subpopulations
achieved through government financing of first-line AEDs
(scenario 1), first- and second-line AEDs (scenario 2), and
first-line AEDs, second-line AEDs, and surgery (scenario
3). The key findings are presented qualitatively in Table 3.
Figure 3.
Cost-effectiveness. Results are over 100 simulations. DALYs, disability-adjusted life years. In row 1 the costs and health benefits are dis-
counted at 3% and aggregated over the 10 years. The costs include both government expenditure and out-of-pocket (OOP) expenditure
for diagnostics, treatments, inpatient costs, and first- and second-line therapies. Row 2 represents the mean nondiscounted total costs
and DALYs averted for the entire Indian population each year. All policy scenarios cover the annual medical costs (consultation, diagnos-
tics, and inpatient). In scenario 1, effective coverage for first-line therapy is 80%, and effective coverage for second-line therapy is 36%.
Second-line treatment and surgery are paid out of pocket. In scenario 2, effective coverage for first-line and second-line therapy is 80%,
and only surgery is paid out of pocket. In scenario 3, effective coverage for first-line and second-line therapy is 80%, and no treatment is
paid out of pocket. Only the top 1% of the population chooses to undergo surgery when it is covered out of pocket. Error bars are the
95% uncertainty range.
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Increasing coverage requires substantial government
investment, especially in the initial stages of the UPF
scenarios. In our analysis we assume an immediate increase
of coverage, and therefore the costs are extremely high in
the first few years. In the first 5 years of scenario 1, the gov-
ernment would spend $220–$255 million ($365–$440 mil-
lion in scenario 2) per year, and in the next 5 years it would
spend $160–$185 million ($285–$325 million in scenario 2)
per year. In scenario 3 the government would spend approxi-
mately $1 billion dollars in year one, $410–$480 million in
the next 4 years, and $320–$390 million each year following
that. The immediate increase in coverage is likely infeasible,
and in reality the higher costs in the initial stages can be
spread out over a longer period. Despite that, this analysis
Figure 4.
Health and economic outcomes per 100,000 persons in each state. Results are over 100 simulations and 10 years; they are presented in
present day values. OOP, out of pocket; DALYs, disability-adjusted life years. States in which the standard error is large and we cannot dif-
ferentiate the results from no effect are grayed out. In the OOP expenditure averted plot (row 3), two states—Assam and Odisha—have
significant negative results; they were grayed out for clarity in the color scale of the maps. All policy scenarios cover the annual medical
costs (consultation, diagnostics, and inpatient). In scenario 1, effective coverage for first-line therapy is 80%, and effective coverage for
second-line therapy is 36%. Second-line treatment and surgery are paid out of pocket. In scenario 2, effective coverage for first-line and
second-line therapy is 80%, and only surgery is paid out of pocket. In scenario 3, effective coverage for first-line and second-line therapy is
80%, and no treatment is paid out of pocket. Only the top 1% of the population chooses to undergo surgery when it is covered out of
pocket.
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points to the substantial initial investment needed, especially
in a scenario with surgery public financing (scenario 3).
We find that the scenario 1 health benefits are high but
the UPF policy offers minimal financial risk protection and
can increase financial risk. The health benefits accrued in
scenario 1 are higher for the lower income quintiles because
their care-seeking increases the most from the baseline sce-
nario, where coverage in this population is the lowest. Our
baseline data on the distribution of health-seeking behavior
by wealth (NSS 60th round, schedule 25)31may even under-
estimate the slope, and therefore the relative health benefits
to the poor in scenario 1. Variations in DALYs averted
across states in scenario 1 primarily reflect the underlying
demographic differences of the states. Approximately 1
million DALYs per year would be averted in India in the
scenario 1 UPF relative to the baseline. Over half of the
averted DALYs would be in the states Uttar Pradesh, Bihar,
Madhya Pradesh, and Rajasthan.
When we consider OOP expenditures that the govern-
ment may not cover in a UPF (e.g., travel costs), the results
of the ECEA are more informative than a standard cost-
effectiveness analysis (CEA). The increased supply of treat-
ment may not be fully utilized by subpopulations that cannot
afford the associated care-seeking costs. The lack of finan-
cial risk protection may mean that the health benefits we
estimate are exaggerated. Moreover, even if the health bene-
fits in scenario 1 seem progressive, the opposite may be true
when a full accounting of costs is undertaken.
In contrast with scenario 1, scenarios 2 and 3 provide sig-
nificant financial risk protection, although their health bene-
fits incremental to those of scenario 1 are small (if scenario
1’s benefits are realized). Indians would spend a mean of
$84 million and $81 million per year less out of pocket in
scenarios 2 and 3, respectively. The UPF in scenario 2 is
progressive and provides the most protection for the poor
and poor states. In our analysis, >50% of the OOP expendi-
ture averted (and DALYs averted) and approximately 70%
of the financial risk protection come from Uttar Pradesh,
Bihar, Madhya Pradesh, and Rajasthan. If financial limita-
tions prevent the government from fully implementing an
epilepsy program, identifying these states—and potentially
others—where the intervention has a high impact can
improve the focus of policies.
Because we assume only the richest 1% of the population
seeks surgery in the baseline, scenario 3 contributes more to
the health of the bottom 99% relative to scenario 2, but it
provides additional financial protection only for the top 1%.
The poor actually spend more out of pocket in scenario 3
than in scenario 2 because of additional care-seeking costs.
Per case travel and lodging (care-seeking) costs would
likely drop in a UPF policy that increases surgery coverage
because new facilities in communities would need to be
built. However, additional expenses would shift toward
building the facilities.
Scenario 2 (increasing coverage of first- and second-line
treatments to 80% and public financing of those therapies)
is similar to the program described by Tripathi et al.11 as the
national epilepsy program currently under consideration in
India. We find that such a program would be cost-effective
for India. Demand-side interventions (e.g., public educa-
tion) to increase care-seeking in a UPF similar to scenario 2
may be needed alongside the supply-side ones (e.g., increas-
ing availability of AEDs and training on AED principles),13
but in the short term this scenario is likely more feasible
than scenario 3, a UPF that also covers surgery. A recent
survey identified 18 centers that conducted presurgical eval-
uation and surgery for epilepsy in India.32 The number of
surgeries performed in the leading centers has increased
over threefold since 1995–2000. However, the facilities are
unevenly dispersed across the country—50% of the facili-
ties are in southern India and several are located around
Delhi, leaving the center, east, and west uncovered—and
two thirds are nongovernmental. To increase the number of
surgeries performed each year, existing facilities need to
expand their epilepsy programs at a more rapid pace and
new facilities need to be built, especially in poorly covered
areas. Clearly, this process will take time, but scenario 3 is
incrementally cost-effective to scenario 2, and progress
toward increasing epilepsy surgery in India can be made
while implementing policies in line with scenario 2.
Evaluating prospective national epilepsy policies with an
agent-based model allows for exploring the distribution of
Table 3. Key findings
Epilepsy treatment
provided in UPF Cost
Cost-effectiveness
(WHO guidelines)
Disease burden
averted
Financial risk
protection
Scenario 1 First-line AEDs High (approximately $220–$255
million per year through year 5,
then $160–$185 million per year)
Very cost-effective High and somewhat
progressive
Low or none
Scenario 2 First- and second-line
AEDs
High (slightly higher than in scenario 1) Very cost-effective High (slightly higher than
in scenario 1 and similarly
progressive)
High and very
progressive
Scenario 3 First- and second-line
AEDs and surgery
Extremely high (extremely high
through year 5, then slightly higher
than in scenario 2)
Very cost-effective High (slightly higher than
in scenario 2 and
similarly progressive)
High (slightly higher
than in scenario 3,
but less progressive)
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impact across different population subgroups, but the accu-
racy and level of detail possible in such an analysis is
restricted by the quality of the input parameters. Here we
extrapolate impact across states and income quintiles based
on the underlying population distribution of those groups,
but we do not capture all potentially relevant covariates.
Improving the model parameters would improve the mod-
el’s estimates. Many psychiatric and somatic disorders, not
considered in the model, are more common among people
with epilepsy than the general population.33 These comor-
bidities impact physician decisions, patient behavior, and
health outcomes. Adverse drug interactions need to be taken
into account by physicians, and comorbidities can increase
readmission,34 increase households’ OOP expenditure, and
affect patients’ decisions. The designing of health services
for epilepsy patients in UPF can further benefit from taking
comorbidities into consideration.
In addition, although this article adds to the discussion on
expanding coverage of epilepsy treatment in India, it does
have several limitations. We assume that both income and
treatment costs will be constant over the 10-year period of
analysis. Furthermore, the costs included in the analysis are
not an exhaustive list of costs associated with the policy sce-
narios described. We do not include the costs of the program
to build new facilities or alter the travel costs paid out of
pocket, presuming they would be lower with higher cover-
age and more facilities.
Our findings highlight the importance of considering the
financial impacts of interventions and moving beyond CEA
and disease burden analyses. Previous analyses have already
shown that increasing first-line epilepsy therapy reduces the
disease burden and is cost-effective,3–5,29,30 and we confirm
that result in our model. However, our results show that a
UPF policy on first-line therapy alone fails to protect from
financial shock, and that affects poor populations the most
adversely. Moreover, the lack of financial risk protection
may mean the health benefits of the policy are not fully real-
ized. A policy that increases the distribution of second-line
therapy further reduces the disease burden (although only
by a small amount), while also providing substantial finan-
cial risk protection. Accordingly, this analysis provides eco-
nomic evidence in support of the proposed national epilepsy
program in India.
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